Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities and Strategies to 2030: COVID-19 Impact and Recovery

This report describes and explains the global vascular endothelial growth factor (VEGF) inhibitor market and covers 2015 to 2020, termed the historic period, and 2020 to 2025 termed the forecast period, along with further forecasts for the period 2025-2030. The report evaluates the market across each region and for the major economies within each region.

The global vascular endothelial growth factor (VEGF) inhibitor market reached a value of nearly $30,312.6 million in 2020, having increased at a compound annual growth rate (CAGR) of 7.8% since 2015. The market is expected to grow from $30,312.6 million in 2020 to $46,635.5 million in 2025 at a rate of 9.0%. The market is then expected to grow at a CAGR of 6.3% from 2025 and reach $63,375.9 million in 2030.

Growth in the historic period resulted from increase in cancer prevalence, strong economic growth in emerging markets, increase in pharmaceutical R&D expenditure, increased healthcare expenditure, government initiatives and rapid growth in elderly population.

Going forward, increasing prevalence of cancer, rising prevalence of age-related macular degeneration (AMD), rise in healthcare expenditure, high potential of emerging economies, high penetration of the biosimilar drugs and increasing geriatric population will drive the growth. Factors that could hinder the growth of the vascular endothelial growth factor (VEGF) inhibitor market in the future include high costs of drugs, rise in interest rates, coronavirus pandemic and side effects.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by drugs type into Eylea, Avastin, Tagrisso, Tecentriq and others. The Eylea market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type, accounting for 23.0% of the total in 2020. Going forward, the tecentriq segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type, at a CAGR of 23.0% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by route of administration into intravenous, intravitreal and oral. The intravenous market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by route of administration, accounting for 34.4% of the total in 2020. Going forward, the oral segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by route of administration type, at a CAGR of 13.7% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by application into oncology and ophthalmology. The oncology market was the largest segment of the vascular endothelial growth factor (VEGF) inhibitor market segmented by application, accounting for 60.1% of the total in 2020. Going forward, the oncology segment is expected to be the fastest growing segment in the vascular endothelial growth factor (VEGF) inhibitor market segmented by application type, at a CAGR of 10.8% during 2020-2025.

The vascular endothelial growth factor (VEGF) inhibitor market is segmented by geography into Asia Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the global vascular endothelial growth factor (VEGF) inhibitor market, accounting for 49.0% of the total in 2020. It was followed by Asia-Pacific, and then the other regions. Going forward, the fastest-growing regions in the vascular endothelial growth factor (VEGF) inhibitor market will be Eastern Europe, and, South America where growth will be at CAGRs of 14.6% and 13.1% respectively. These will be followed by Africa, and Middle East, where the markets are expected to grow at CAGRs of 12.2% and 12.0% respectively.

The pandemic has negatively impacted the VEGF market as patients opted for deferred care, as they did not want to visit hospitals or clinics to avoid exposure to the virus. According to a study at The China Medical University First Hospital Department of Ophthalmology during the pandemic, the number of patients who received the VEGF inhibitor injections in the hospital from January 2020 to June 2020 declined by 70%, thus negatively impacting the growth of the market.

The vascular endothelial growth factor (VEGF) inhibitor market is highly consolidated, with small number of large players dominating the market. The top 10 companies in the market occupied 99% of market share in the global vascular endothelial growth factor (VEGF) inhibitor market. Major players in the market include F. Hoffmann-La Roche AG, Bayer AG, Regeneron Pharmaceuticals Inc., Astrazeneca Plc. and Novartis AG.

The top opportunities in the vascular endothelial growth factor (VEGF) inhibitor market segmented by drugs type will arise in the tecentriq segment, which will gain $4,596.9 million of global annual sales by 2025. The top opportunities in segment by route of administration will arise in the oral segment, which will gain $8,830.4 million of global annual sales by 2025. The top opportunities in segment by application will arise in the oncology segment, which will gain $12,263.3 million of global annual sales by 2025. The vascular endothelial growth factor (VEGF) inhibitor market size will gain the most in the USA at $7,015.6 million.

Market-trend-based strategies for the vascular endothelial growth factor (VEGF) inhibitor market include offering combination therapies to patients in order to combat advanced cancers and improve patient life, focusing on strategic collaborations to boost innovations and establish category leadership, investing extensively in R&D activities for the development of effective and innovative drugs, focusing on the production of biosimilars in order to cater to a wider market by making treatment more affordable and focusing on reducing dosages for wet age-related macular degeneration (AMD) in order to improve patient welfare.

Player-adopted strategies in the vascular endothelial growth factor (VEGF) inhibitor market include improving business through new product launches and expanding in newer geographies through strategic collaborations.

To take advantage of the opportunities, the publisher recommends the vascular endothelial growth factor (VEGF) inhibitor market companies to focus on new delivery system, research & development, combination therapy, provide competitively priced offerings, premium pricing for innovator drugs, expand in countries with growing geriatric population, expand in emerging markets, promoting drugs through physicians and NGOs, leverage e-commerce tools to maximize reach and targeting people suffering from cancer and eye disorders.